Statements (26)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
gptkb:clinical_trial
|
| gptkbp:clinicalTrials.gov_Identifier |
NCT00458393
|
| gptkbp:endDate |
2010
|
| gptkbp:fullName |
Pre-Exposure Prophylaxis Initiative trial
|
| https://www.w3.org/2000/01/rdf-schema#label |
iPrEx trial
|
| gptkbp:location |
gptkb:Brazil
gptkb:Ecuador gptkb:India gptkb:Peru gptkb:South_Africa gptkb:Thailand gptkb:United_States |
| gptkbp:principalInvestigator |
gptkb:Robert_M._Grant
|
| gptkbp:publicationYear |
2010
|
| gptkbp:publishedIn |
gptkb:New_England_Journal_of_Medicine
|
| gptkbp:result |
HIV infection incidence
Higher efficacy with greater adherence Truvada reduced HIV risk by 44% overall |
| gptkbp:sponsor |
gptkb:National_Institutes_of_Health
gptkb:Bill_&_Melinda_Gates_Foundation |
| gptkbp:startYear |
2007
|
| gptkbp:studiedIntervention |
oral Truvada (emtricitabine/tenofovir)
|
| gptkbp:studiedPopulation |
gptkb:men_who_have_sex_with_men
transgender women |
| gptkbp:bfsParent |
gptkb:PrEP
|
| gptkbp:bfsLayer |
6
|